SCHEMBL5580098

SCHEMBL5580098

Cc1cn([C@H]2C[C@H](O)[C@@H](COC3CCC3)O2)c(=O)[nH]c1=O

nearest known ligand 0.66

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.62
TK1 P04183 3/20 0.62
TYMS P04818 1/20 0.56
BCHE P06276 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20404661 0.96 TK1 (0.67) POLBTK1TYMSBCHE
SCHEMBL20115166 0.86 POLB (0.63) POLBTK1TYMS
SCHEMBL21163947 0.86 POLB (0.63) POLBTK1TYMS
SCHEMBL3514019 0.86 POLB (0.63) POLBTK1TYMS
SCHEMBL20109714 0.86 POLB (0.63) POLBTK1TYMS
SCHEMBL3345511 0.86 POLB (0.63) POLBTK1TYMS
SCHEMBL6379335 0.85 POLB (0.68) POLBTK1TYMSBCHE
SCHEMBL17236294 0.85 TK1 (0.69) POLBTK1TYMSBCHE
SCHEMBL12918450 0.85 TK1 (0.69) POLBTK1TYMSBCHE
SCHEMBL22943603 0.85 TK1 (0.69) POLBTK1TYMSBCHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070032446-A1 GAPPED 2' MODIFIED OLIGONUCLEOTIDES ISIS PHARMACEUTICALS, INC. (US) 2007-02-08 US disclosed
US-20060270624-A1 GAPPED 2' MODIFIED OLIGONUCLEOTIDES ISIS PHARMACEUTICALS, INC. (US) 2006-11-30 US disclosed
EP-1695979-A2 Gapped 2' modified oligonucleotides ISIS PHARMACEUTICALS, INC. (US) 2006-08-30 EP disclosed
EP-1044987-B1 Gapped 2'-modified oligonucleotides ISIS PHARMACEUTICALS INC (US) 2006-02-15 EP disclosed
US-20050112563-A9 Gapped 2' modified oligonucleotides ISIS PHARMACEUTICALS, INC. 2005-05-26 US disclosed
US-20040038274-A1 Gapped 2' modified oligonucleotides ISIS PHARMACEUTICALS, INC. 2004-02-26 US disclosed
US-20020160379-A1 Gapped 2' modified oligonucleotides ISIS PHARMACEUTICALS, INC. 2002-10-31 US disclosed
US-6326199-B1 Gapped 2′ modified oligonucleotides ISIS PHARMACEUTICALS, INC. 2001-12-04 US disclosed
EP-0618925-B1 ANTISENSE OLIGONUCLEOTIDES ISIS PHARMACEUTICALS INC (US) 2001-08-29 EP disclosed
US-6146829-A MODIFYING RNA IN TEST SOLUTION CONTAINING RNASE HI BY HYBRIDIZING WITH OLIGONUCLEOTIDE HAVING NUCLEOTIDES WITH 2'DEOXY-ERYTHRO-PENTOFURANOSYL SUGAR MOIETIES; ACTIVATES RNASE AND RESISTS NUCLEASE DEGRADATION ISIS PHARMACEUTICALS, INC. (US) 2000-11-14 US disclosed
EP-1044987-A2 Gapped 2'-modified oligonucleotides ISIS PHARMACEUTICALS, INC. (US) 2000-10-18 EP disclosed
US-5856455-A INCREASED NUCLEASE RESISTANCE; ATLEAST ONE NUCLEOTIDE UNIT BEARS AMINOALKOXY, ALLYLOXY, OR IMIDAZOLYLALKOXY 2'-SUBSTITUENT GROUP AND PLURITY OF NUCLEOTIDE GROUP HAVE 2'-DEOXY-ERYTHROPENTOFURANOSYL SUGAR UNITS ISIS PHARMACEUTICALS, INC. (US) 1999-01-05 US disclosed
US-5623065-A MODIFIED OLIGONUCLEOTIDE WHICH HAS BINDING AFFINITY TO COMPLEMENTARY NUCLEIC ACID, INHIBITS TRANSLOCATION OF SAID ACID, PROMOTES RIBONUCLEASE CLEAVAGE IN VITRO ISIS PHARMACEUTICALS, INC. (US) 1997-04-22 US disclosed
EP-0618925-A4 GAPPED 2' MODIFIED OLIGONUCLEOTIDES. ISIS PHARMACEUTICALS INC (US) 1997-01-02 EP disclosed
EP-0618925-A1 GAPPED 2' MODIFIED OLIGONUCLEOTIDES ISIS PHARMACEUTICALS, INC. (US) 1994-10-12 EP disclosed
WO-1993013121-A1 GAPPED 2' MODIFIED OLIGONUCLEOTIDES ISIS PHARMACEUTICALS, INC. (US) 1993-07-08 WO disclosed